Personalized medicine (personalized psychiatry in a specific setting) is a new model
towards individualized care, in which knowledge from genomics and other omic pillars …

Personalized medicine has become increasingly relevant to many medical fields, promising
more efficient drug therapies and earlier intervention. The development of personalized …

Objective: The antidepressant escitalopram is predominantly metabolized by the
polymorphic CYP2C19 enzyme. The authors investigated the effect of CYP2C19 genotype …

Major depressive disorder (MDD) is complex and multifactorial, posing a major challenge of
tailoring the optimal medication for each patient. Current practice for MDD treatment mainly …

Background Antidepressants are a first-line treatment for depression. However, only a third
of individuals experience remission after the first treatment. Common genetic variation, in …

Disrupted serotonergic neurotransmission has long been implicated in major depressive
disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line of …

Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies
considerably between patients. The International SSRI Pharmacogenomics Consortium …

Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed antidepressants.
They regulate serotonergic neurotransmission, but it remains unclear how altered …

Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major
depressive disorder (MDD), yet their mechanisms of action are not fully understood and their …

Millions of patients suffer from major depressive disorder (MDD), but many do not respond to
selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics …